Literature DB >> 9080598

Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning.

S S Deshpande1, R E Sheridan, M Adler.   

Abstract

Various 4- and 8-aminoquinolines, which are effective antimalarial agents, were examined as potential pretreatment compounds for prolongation of the time to 50% block of nerve-elicited muscle twitches in isolated mouse diaphragms exposed to botulinum type A neurotoxin. The 4-aminoquinolines (chloroquine, amodiaquine) and quinacrine, an acridine derivative similar to chloroquine, prolonged the time required for botulinum type A neurotoxin to block neuromuscular transmission by more than 3-fold; 8-aminoquinolines (primaquine and WR242511) had no antibotulinum type A neurotoxin activity. Pyrimethamine, an antimalarial drug lacking the quinoline ring structure, was also ineffective. Rank order potencies based on equimolar effective concentrations for the test compounds were quinacrine > amodiaquine > chloroquine > quinine or quinidine. Maximum protection from botulinum type A neurotoxin-induced neuromuscular block was achieved when muscles were exposed to drug prior to or simultaneously with the toxin. A delay of more than 20 min abolished the protective ability of the antimalarial agents, presumably owing to the release of the toxin from endosomes in quantities sufficient to initiate neuromuscular block. All of the test compounds except quinine and quinidine depressed muscle contractions when concentrations exceeded 20 microM. In addition, amodiaquine at 50 microM induced muscle contracture. A combination of agents at low concentrations that act at different steps of botulinum type A neurotoxin poisoning potentiated the prolongation of time to 50% block in an approximately additive fashion. Thus N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (2 microM) and quinacrine (5 microM), when administered in combination, produced up to a 4-fold increase in time to 50% block. A similar level of protection with quinacrine alone required a 4-fold increase in the aminoquinoline concentration. Although the mechanism of protection by these antimalarial agents is probably through the raising of endosomal pH, the possibility that some of these drugs could also act by inhibiting toxin-induced channel formation cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9080598     DOI: 10.1016/s0041-0101(96)00147-x

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  9 in total

1.  SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons.

Authors:  Erkan Kiris; James C Burnett; Jonathan E Nuss; Laura M Wanner; Brian D Peyser; Hao T Du; Glenn Y Gomba; Krishna P Kota; Rekha G Panchal; Rick Gussio; Christopher D Kane; Lino Tessarollo; Sina Bavari
Journal:  Neurotox Res       Date:  2015-03-18       Impact factor: 3.911

2.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

3.  Black tea extract, thearubigin fraction, counteract the effects of botulinum neurotoxins in mice.

Authors:  E Satoh; T Ishii; Y Shimizu; S Sawamura ; M Nishimura
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

4.  Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.

Authors:  Paul T Bremer; Michael Adler; Cecilia H Phung; Ajay K Singh; Kim D Janda
Journal:  J Med Chem       Date:  2017-01-03       Impact factor: 7.446

5.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

6.  Lipid and cationic polymer based transduction of botulinum holotoxin, or toxin protease alone, extends the target cell range and improves the efficiency of intoxication.

Authors:  Chueh-Ling Kuo; George Oyler; Charles B Shoemaker
Journal:  Toxicon       Date:  2009-10-21       Impact factor: 3.033

7.  Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.

Authors:  Virginia Roxas-Duncan; Istvan Enyedy; Vicki A Montgomery; Vanessa S Eccard; Marco A Carrington; Huiguo Lai; Nizamettin Gul; David C H Yang; Leonard A Smith
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

Review 8.  The zinc-dependent protease activity of the botulinum neurotoxins.

Authors:  Frank J Lebeda; Regina Z Cer; Uma Mudunuri; Robert Stephens; Bal Ram Singh; Michael Adler
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

Review 9.  The evolving field of biodefence: therapeutic developments and diagnostics.

Authors:  James C Burnett; Erik A Henchal; Alan L Schmaljohn; Sina Bavari
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.